Founded in October 2019, Kriya has lofty ambitions, describing its ultimate goal as “eliminating human suffering” from disease. CEO Shankar Ramaswamy says the company stands apart from rivals because its research platform can overcome challenges that have hampered the gene therapy field in research, development and manufacturing.
Ramaswamy is the brother of Roivant Sciences founder and presidential hopeful Vivek Ramaswamy. He co-founded Kriya after stints at Roivant and Sio Gene Therapies, which folded in December. He says Kriya has won over investors with its in-house manufacturing capabilities and ability to develop multiple gene therapies in parallel.
